Gilead Sciences studies show benefits of switching to HIV drug Biktarvy

Gilead Sciences has announced the findings of two new clinical trials that demonstrate the benefits of switching to its HIV therapy Biktarvy.

Data from the first phase III trial, Study 1844, highlighted the efficacy and safety of switching from a regimen containing abacavir, dolutegravir and lamivudine to Biktarvy among virologically suppressed adults with HIV.

After 48 weeks, Biktarvy was found to be statistically non-inferior to the alternative regimen, with a numerically lower incidence of mild or moderate drug-related adverse events and no treatment-emergent resistance.

Meanwhile, data from another phase III trial – Study 1961 – indicated that women with HIV may benefit from switching from a boosted protease inhibitor or elvitegravir-containing regimen to Biktarvy, with similarly positive non-inferiority and treatment-emergent resistance trends observed after 48 weeks.

Dr Norbert Bischofberger, Gilead's executive vice-president for research and development and chief scientific officer, said: "Following the recent approval of Biktarvy in the US, we look forward to working to expand the availability of this novel therapy to patients around the world."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.